PATENT CLAIM ANALYSIS

Application Number: 16155220
Application Type: Utility
Filing Date: 2018-10
Publication Date: 2019-02
Patent Classification: ["435", "006140"]

Abstract:
The present invention relates to a gene for predicting or diagnosing the prognosis of early-stage breast cancer and to a use thereof, and more specifically relates to a genetic marker for predicting or diagnosing the prognosis of breast cancer, including TRBC1 (T cell receptor beta constant 1), BTN3A2 (butyrophilin, subfamily 3, member A2) or HLA-DPA1 (major histocompatibility complex, class II, DP alpha 1) for providing information necessary for predicting or diagnosing the prognosis of a breast cancer patient. The genetic marker of the present invention allows the prediction or diagnosis of the prognosis of a breast cancer patient, and can therefore advantageously be used for the purpose of providing a direction as to the future course of breast cancer treatment, including a decision on whether anticancer therapy is necessary.

Claim (Index 10):
The method of  claim 7 , wherein an overexpression of the i-gene indicates a good prognosis of breast cancer, while an overexpression of the p-gene indicates a poor prognosis of breast cancer.

Metadata:
- Claim Count in Document: 9.0
- Percentile: 97.0
- Lexical Diversity: 1.97297
- Patent Class: 435.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['13737349', '12214782', '12757931', '13584369', '10268730']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.672781733739148
- 35 USC 102 Novelty (BERT): 0.5355939721578267
- Combined Prediction Score: 0.6590629575810159
- Mean Citation Score: 357.28054000000014
- Max Citation Score: 401.77496
- Similarity Product: 207.8505716532564

Labels:
- Claim Label 101: 0
- Claim Label 102: 0
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 0
- Label 101 Adjusted: 0

Dataset: test